Day One Biopharmaceuticals Inc (DAWN)vsMerck & Company Inc (MRK)
DAWN
Day One Biopharmaceuticals Inc
$21.53
0.00%
HEALTHCARE · Cap: $2.22B
MRK
Merck & Company Inc
$130.40
-1.11%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 41477% more annual revenue ($65.77B vs $158.18M). MRK leads profitability with a 13.6% profit margin vs -67.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).
DAWN
Avoid30
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DAWN.
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.9% year-over-year
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
ROE of -22.7% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DAWN
The strongest argument for DAWN centers on Revenue Growth. Revenue growth of 83.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : DAWN
The primary concerns for DAWN are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
DAWN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
DAWN is growing revenue faster at 83.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Day One Biopharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?